[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507255":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":16,"responsibleParty":36,"collaborators":38,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":7,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"SOLTI Breast Cancer Research Group","OTHER",null,[9,13],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"GENETIC","Liquid Biopsy","Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"Archival Tumor DNA sequencing","Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis",[17],{"facility":18,"status":19,"city":20,"state":7,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"SOLTI Cancer Research Group","RECRUITING","Barcelona","08008","Spain","ES",{"type":25,"coordinates":26},"Point",[27,28],2.15899,41.38879,{"lat":28,"lon":27},[31],{"name":32,"role":33,"phone":34,"phoneExt":7,"email":35},"HOPE-Prostate Study Team","CONTACT","(+34) 93 343 63 02","prostata.hope@gruposolti.org",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[39,42,44,46,48,50],{"name":40,"class":41},"Pfizer","INDUSTRY",{"name":43,"class":41},"AstraZeneca",{"name":45,"class":41},"Merck Sharp & Dohme LLC",{"name":47,"class":41},"Advanced Accelerator Applications",{"name":49,"class":41},"Astellas Pharma Inc",{"name":51,"class":41},"Guardant Health, Inc.","100507255","feasibility-and-impact-of-liquid-biopsy-genomic-profiling-on-treatment-patients-with-metastatic-prostate-cancer-in-spain-solti-2102-100507255",false,"NCT05885009","Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)","Real World Clinical Practice Study to Assess the Feasibility and Impact of Liquid Biopsy-based Genomic Profiling on Treatment Decision Making for Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)","HOPE-PROSTATE","Inclusion Criteria:\n\n1. Male patients living in Spain.\n2. Age ≥18 years.\n3. Signed informed consent before any screening procedure.\n4. Metastatic PC of any subtype confirmed both pathologically and radiologically (stage IV disease).\n5. The subjects must be about to receive, or receiving, or will have completed treatment for their metastatic disease with any line of treatment in either a clinical trial or the standard of care healthcare setting.\n6. Eastern Cooperative Oncology Group (ECOG) 0-1.\n\nExclusion Criteria:\n\n1. Inability to consent or conform to the processes involved in a clinical study.\n2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.","MALE","18 Years",{"count":63,"type":64},240,"ESTIMATED","OBSERVATIONAL","HOPE Prostate is an observational study that aims at promoting research against metastatic prostate cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic prostate cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease, and to provide a blood sample and an archival tumor biopsy. In HOPE Prostate these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will try to enumerate future therapeutic options that match patient history and his genomic profile. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years.\n\nThe study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic prostate cancer patients.",[68],"Metastatic Prostate Cancer",[70,71,72,73,74],"molecular advisory board","molecular tumor board","genomic data","targeted therapy","patient-centric trials","2025-08-01",{"date":77,"type":78},"2025-08-06","ACTUAL",{"date":80,"type":78},"2023-03-28",{"date":82,"type":64},"2028-03-28",{"name":5,"class":6},1]